GlycoMimetics Inc (GLYC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH141235D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

November 2018

Total pages

55

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

GlycoMimetics Inc (GlycoMimetics) is a clinical-stage biotechnology company that research, develops and commercializes small molecule drugs. The company's products comprise rivipansel (GMI-1070), under phase III clinical trial is an anti-inflammatory compound to treat vaso-occlusive crisis of sickle cell disease and blood cancers. It also provides GMI-1271, galectin inhibitors, GMI-1359, GMI-1051 and research programs. GlycoMimetics designs and tests viral and bacterial entry inhibitors dendritic cell receptor. The company uses proprietary glycobiology technology to develop treatments for diseases. It also offers clinical research programs. GlycoMimetics is headquartered in Rockville, Maryland, the US.

GlycoMimetics Inc (GLYC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

GlycoMimetics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GlycoMimetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

IAVI, GlycoMimetics, And Glycosensors and Diagnostics Enter Into Agreement To Develop AIDS Vaccine 11

Equity Offering 12

GlycoMimetics Prices Public Offering of Shares for USD119 Million 12

GlycoMimetics Raises USD92.6 Million in Public Offering of Shares 14

GlycoMimetics Raises USD21 Million in Public Offering of Shares 16

GlycoMimetics Raises USD3 Million in First Tranche of Public Offering of Shares 18

GlycoMimetics Completes IPO For USD 64.4 Million 19

GlycoMimetics Inc-Key Competitors 21

GlycoMimetics Inc-Key Employees 22

GlycoMimetics Inc-Locations And Subsidiaries 23

Head Office 23

Recent Developments 24

Financial Announcements 24

Nov 02, 2018: GlycoMimetics reports third quarter 2018 results and highlights recent company achievements 24

Aug 09, 2018: Glycomimetics reports second quarter 2018 results and highlights recent company achievements 26

May 03, 2018: GlycoMimetics Reports First Quarter 2018 Results 27

Mar 06, 2018: GlycoMimetics Reports Fourth Quarter and Year-End 2017 Results 28

Nov 08, 2017: GlycoMimetics Reports Program Updates and Third Quarter 2017 Results 29

Aug 03, 2017: GlycoMimetics Reports Program Updates and Second Quarter 2017 Results 31

May 08, 2017: GlycoMimetics Reports Program Updates and First Quarter 2017 Results 33

Mar 01, 2017: GlycoMimetics Reports Fourth Quarter and Year-End 2016 Results 34

Corporate Communications 35

Jun 12, 2017: GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors 35

Mar 13, 2017: GlycoMimetics Appoints Scott Koenig of MacroGenics to Board of Directors 36

Product News 37

06/05/2017: GlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting 37

05/17/2017: GlycoMimetics' GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia 38

Product Approvals 39

May 25, 2017: GlycoMimetics' GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia 39

Clinical Trials 40

May 30, 2018: GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy 40

Mar 14, 2018: GlycoMimetics to Present New Preclinical Data for GMI-1271 at AACR Annual Meeting 2018 41

Mar 14, 2018: GlycoMimetics to Present New Preclinical Data for GMI-1359 at AACR Annual Meeting 2018 42

Mar 05, 2018: GlycoMimetics Announces Design of Phase 3 Clinical Trial for GMI-1271 in Relapsed/Refractory AML 43

Feb 08, 2018: GlycoMimetics Enters into Agreement with HOVON to Initiate Study Startup Activities for Planned Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Chemotherapy 44

Dec 12, 2017: GlycoMimetics Reports Improvements in Median Overall Survival Versus Historical Matched Controls for Two AML Patient Subgroups in Phase 1/2 Trial for GMI-1271 45

Nov 01, 2017: GlycoMimetics to Highlight GMI-1271 Clinical Data and Underlying, Differentiated Mechanism of Action in Oral Presentations at 59th Annual ASH Meeting 46

May 18, 2017: GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML 48

May 02, 2017: GlycoMimetics Announces Publication of Preclinical Data Showing Role of E-selectin Ligands in Multiple Myeloma 50

Apr 20, 2017: GlycoMimetics to Present New AML Clinical Data at ASCO 2017 Annual Meeting 51

Mar 07, 2017: GlycoMimetics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271 52

Mar 02, 2017: GlycoMimetics to Present New Preclinical Data of GMI-1271 at AACR Annual Meeting 2017 53

Mar 02, 2017: GlycoMimetics to Present New Preclinical Data of GMI-1359 at AACR Annual Meeting 2017 54

Appendix 55

Methodology 55

About GlobalData 55

Contact Us 55

Disclaimer 55


List of Figure

List of Figures

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List of Table

List of Tables

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

GlycoMimetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

GlycoMimetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

IAVI, GlycoMimetics, And Glycosensors and Diagnostics Enter Into Agreement To Develop AIDS Vaccine 11

GlycoMimetics Prices Public Offering of Shares for USD119 Million 12

GlycoMimetics Raises USD92.6 Million in Public Offering of Shares 14

GlycoMimetics Raises USD21 Million in Public Offering of Shares 16

GlycoMimetics Raises USD3 Million in First Tranche of Public Offering of Shares 18

GlycoMimetics Completes IPO For USD 64.4 Million 19

GlycoMimetics Inc, Key Competitors 21

GlycoMimetics Inc, Key Employees 22

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022